Research Analysts Offer Predictions for KALV Q4 Earnings

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) – Investment analysts at Leerink Partnrs issued their Q4 2025 earnings per share (EPS) estimates for shares of KalVista Pharmaceuticals in a research report issued to clients and investors on Tuesday, March 25th. Leerink Partnrs analyst J. Schwartz anticipates that the specialty pharmaceutical company will post earnings per share of ($0.77) for the quarter. The consensus estimate for KalVista Pharmaceuticals’ current full-year earnings is ($3.56) per share. Leerink Partnrs also issued estimates for KalVista Pharmaceuticals’ Q1 2026 earnings at ($0.72) EPS, Q2 2026 earnings at ($0.60) EPS, Q3 2026 earnings at ($0.53) EPS, Q4 2026 earnings at ($0.47) EPS, FY2026 earnings at ($2.41) EPS and FY2027 earnings at ($1.27) EPS.

Other equities research analysts have also issued research reports about the stock. Bank of America began coverage on shares of KalVista Pharmaceuticals in a research note on Wednesday, December 18th. They issued a “buy” rating and a $22.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of KalVista Pharmaceuticals in a research note on Friday, March 14th. Citizens Jmp upgraded KalVista Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 31st. TD Cowen started coverage on KalVista Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating and a $30.00 price target for the company. Finally, JMP Securities assumed coverage on KalVista Pharmaceuticals in a research note on Friday, January 31st. They set an “outperform” rating and a $19.00 price objective on the stock. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $24.83.

KalVista Pharmaceuticals Stock Down 3.3 %

Shares of NASDAQ KALV opened at $11.93 on Friday. The business has a 50 day moving average price of $10.56 and a two-hundred day moving average price of $10.26. KalVista Pharmaceuticals has a fifty-two week low of $7.30 and a fifty-two week high of $15.50. The firm has a market cap of $593.11 million, a PE ratio of -3.28 and a beta of 0.76.

Insiders Place Their Bets

In other news, major shareholder Venrock Healthcare Capital Par bought 43,707 shares of the firm’s stock in a transaction on Thursday, January 30th. The stock was purchased at an average price of $8.76 per share, for a total transaction of $382,873.32. Following the transaction, the insider now owns 4,986,480 shares in the company, valued at approximately $43,681,564.80. This trade represents a 0.88 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Benjamin L. Palleiko sold 5,104 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $9.82, for a total transaction of $50,121.28. Following the completion of the sale, the chief executive officer now owns 278,855 shares in the company, valued at $2,738,356.10. The trade was a 1.80 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have purchased 236,055 shares of company stock valued at $2,162,146 and have sold 17,292 shares valued at $184,625. 10.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Quest Partners LLC acquired a new stake in KalVista Pharmaceuticals in the 3rd quarter valued at about $175,000. Connor Clark & Lunn Investment Management Ltd. lifted its stake in KalVista Pharmaceuticals by 114.4% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 22,949 shares of the specialty pharmaceutical company’s stock valued at $266,000 after purchasing an additional 12,245 shares during the last quarter. Intech Investment Management LLC bought a new stake in KalVista Pharmaceuticals during the third quarter worth approximately $126,000. Citigroup Inc. boosted its holdings in KalVista Pharmaceuticals by 6.8% during the third quarter. Citigroup Inc. now owns 305,504 shares of the specialty pharmaceutical company’s stock worth $3,538,000 after buying an additional 19,440 shares in the last quarter. Finally, FMR LLC grew its position in KalVista Pharmaceuticals by 22.9% in the third quarter. FMR LLC now owns 66,423 shares of the specialty pharmaceutical company’s stock worth $769,000 after buying an additional 12,397 shares during the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).